Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5S4GK)

• Drug Name: Flavin-Adenine Dinucleotide Drug Info
• Synonyms: flavin adenine dinucleotide; Flavin-adenine dinucleotide; 146-14-5; FAD; flavitan; Flavine-adenine dinucleotide; Flanin F; UNII-ZC44YTI8KK; Flamitajin B; Adenine-flavin dinucleotide; Adenine-flavine dinucleotide; ZC44YTI8KK; Flavine adenosine diphosphate; Riboflavin 5'-adenosine diphosphate; Flaziren (free acid); Riboflavin-adenine dinucleotide; Adenine-riboflavin dinucleotide; Adenine-riboflavine dinucleotide; Riboflavine-adenine dinucleotide; Isoalloxazine-adenine dinucleotide; Flavin adenin dinucleotide; CHEBI:16238; flavin a

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 643975
  ChEBI ID: CHEBI:16238
  CAS Number: CAS 146-14-5
  TTD Drug ID: DM5S4GK

Molecule-Related Drug Atlas

Drug(s) Targeting Nitric-oxide synthase brain (NOS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[4]
NXN-462	DMWVBS2	Headache	8A80-8A84	Phase 2	[5]
L-NIL	DM6Y49D	N. A.	N. A.	Terminated	[6]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[2]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[2]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[7]
Formic Acid	DMNFZC6	Discovery agent	N.A.	Investigative	[2]
2'-Monophosphoadenosine 5'-Diphosphoribose	DME9S8M	Discovery agent	N.A.	Investigative	[2]
6-isobutyl-4-methylpyridin-2-amine	DM2XB68	Discovery agent	N.A.	Investigative	[8]
7-Methyl-[1,4]thiazepan-(5E)-ylideneamine	DMUCJA6	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Bacterial Flavohemoglobin (Bact hmp)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[2]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[7]
2-(N-Morpholino)-Ethanesulfonic Acid	DMZVHSB	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Glutathione reductase (GR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oxidized glutathione	DM9EQC0	Breast cancer	2C60-2C65	Approved	[10]
Golden phosphorous acetyletic compound 2	DMYJ15A	N. A.	N. A.	Patented	[11]
Terpyridineplatinum(II) complexe 3	DM54EFD	N. A.	N. A.	Patented	[11]
Terpyridineplatinum(II) complexe 4	DMOV86T	N. A.	N. A.	Patented	[11]
Golden phosphorous acetyletic compound 1	DMVAKUI	N. A.	N. A.	Patented	[11]
Acyl oxymethyl acrylamide ester derivative 1	DMXTUE1	N. A.	N. A.	Patented	[11]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[2]
3-Sulfinoalanine	DMILTRN	N. A.	N. A.	Investigative	[2]
1-(2'-chlorophenyl)penta-1,4-dien-3-one	DMKTZSY	Discovery agent	N.A.	Investigative	[12]
Trans-(R(S))-2-Hydroxy-1-phenylethyl nitrate	DMXC98D	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting Bacterial Fumarate reductase flavoprotein (Bact frdA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thiabendazole	DM7YCK3	Ascariasis	1F62	Approved	[14]
Oxantel pamoate	DMZ30JT	Trichuris trichiura infection	1F6G	Approved	[14]
Morantel tartrate	DM560Y3	Mature gastrointestinal nematode infection	1F6Y	Approved	[14]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[7]
Fumarate	DM9VLS2	Discovery agent	N.A.	Investigative	[2]
2,3-DIMETHYL-1,4-NAPHTHOQUINONE	DMGXVBA	Discovery agent	N.A.	Investigative	[7]
Citraconic acid	DMCIM9A	Discovery agent	N.A.	Investigative	[15]
2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL	DMUZDSC	Discovery agent	N.A.	Investigative	[7]
2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE	DMJ3ATL	Discovery agent	N.A.	Investigative	[7]
Malate Like Intermediate	DM4OQWZ	Discovery agent	N.A.	Investigative	[15]

Drug(s) Targeting Xanthine dehydrogenase/oxidase (XDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopurinol	DMLPAOB	Gout	FA25	Approved	[16]
Febuxostat	DMDEXQ0	Hyperuricaemia	5C55.Y	Approved	[17]
Fosdenopterin	DMR0TYK	Molybdenum cofactor deficiency	5B5K.A	Approved	[18]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[19]
Oxypurinol	DMURH4X	Heart failure	BD10-BD13	Phase 2/3	[20]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[21]
Topiroxostat	DMA04DE	Gout	FA25	Phase 2	[22]
TMX-049	DME8PFQ	Diabetic nephropathy	GB61.Z	Phase 2	[23]
LC-350189	DMHT3CB	Gout	FA25	Phase 1	[24]
Azaindole derivative 5	DMD2BL3	N. A.	N. A.	Patented	[25]

Drug(s) Targeting Quinone reductase 1 (NQO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARQ 761	DMH5CAL	Pancreatic cancer	2C10	Phase 2	[26]
Coenzyme Q10 analog	DMO0VGH	Huntington disease	8A01.10	Phase 2	[27]
BioE-743	DM7PT8R	Leigh syndrome	5C53.24	Phase 2	[4]
NSC-645808	DMMBAR3	Discovery agent	N.A.	Investigative	[28]
NSC-106080	DMR6P9S	Discovery agent	N.A.	Investigative	[29]
NSC-99528	DMXZAIG	Discovery agent	N.A.	Investigative	[29]
NSC-354279	DMVL51I	Discovery agent	N.A.	Investigative	[28]
Duroquinone	DML7YPS	Discovery agent	N.A.	Investigative	[2]
Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate	DMJQTIK	Discovery agent	N.A.	Investigative	[30]
3-Benzyl-4-hydroxy-2H-benzo[h]chromen-2-one	DMA5EHC	Discovery agent	N.A.	Investigative	[30]

Drug(s) Targeting Quinone reductase 2 (NQO2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[7]
NSC-645809	DMPJQZG	Breast cancer	2C60-2C65	Phase 2	[31]
Prolarix	DMZIQ8G	Solid tumour/cancer	2A00-2F9Z	Phase 2	[32]
CB1954	DMVP4YK	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[2]
2-iodo-melatonin	DMSEIUP	Discovery agent	N.A.	Investigative	[33]
3,4,5-Trimethoxy-4'-amino-trans-stilbene	DMDBOJ5	Discovery agent	N.A.	Investigative	[34]
NSC-645808	DMMBAR3	Discovery agent	N.A.	Investigative	[31]
decynium 22	DMWCTZ7	Discovery agent	N.A.	Investigative	[29]
NSC-106080	DMR6P9S	Discovery agent	N.A.	Investigative	[29]
NSC-99528	DMXZAIG	Discovery agent	N.A.	Investigative	[29]

Drug(s) Targeting Dihydrothymine dehydrogenase (DPYD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[35]
Eniluracil	DM96NCR	Hyperlipidaemia	5C80	Phase 2	[36]
RO-09-4889	DMQ65YW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[37]
FL-386	DMUQN83	Hyperlipidaemia	5C80	Discontinued in Phase 2	[38]
5-Iodouracil	DM4O6I5	Discovery agent	N.A.	Investigative	[2]
(5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione	DMA5DO2	Discovery agent	N.A.	Investigative	[2]
6-Carboxymethyluracil	DM9MPDK	Discovery agent	N.A.	Investigative	[2]
Uracil	DMNPO9Q	Discovery agent	N.A.	Investigative	[39]

Drug(s) Targeting Trypanosoma Dihydrolipoamide dehydrogenase (Trypano LPD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[2]

Drug(s) Targeting Monoamine oxidase type B (MAO-B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selegiline Hydrochloride	DM3VR1L	Parkinson disease	8A00.0	Approved	[40]
Phenelzine	DMHIDUE	Depression	6A70-6A7Z	Approved	[41]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[42]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[43]
Safinamide mesylate	DM0J2ZT	Parkinson disease	8A00.0	Approved	[44]
Rasagiline	DM3WKQ4	Parkinson disease	8A00.0	Approved	[45]
Sulphadoxine	DMZI2UF	Malaria	1F40-1F45	Approved	[46]
Pargyline	DMM0HR1	Hypertension	BA00-BA04	Approved	[47]
Indeloxazine	DMWO3N6	Dementia	6D80-6D86	Approved	[48]
Budipine	DMODHQI	Migraine	8A80	Approved	[49]

Drug(s) Targeting Monoamine oxidase type A (MAO-A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Moclobemide	DMNZWL7	Depression	6A70-6A7Z	Approved	[50]
Tranylcypromine	DMGB5RE	Major depressive disorder	6A70.3	Approved	[51]
Clorgyline	DMCEUJD	Parkinson disease	8A00.0	Approved	[52]
Isocarboxazid	DMAF1NB	Depression	6A70-6A7Z	Approved	[53]
TRYPTAMINE	DMAFPHB	N. A.	N. A.	Phase 3	[54]
Psoralen	DMIZJ8M	N. A.	N. A.	Phase 3	[55]
CHF-3381	DMQ2O8V	Neuropathic pain	8E43.0	Phase 2	[56]
Ladostigil	DMJSY3Q	Alzheimer disease	8A20	Phase 2	[57]
CX157	DMS2WB5	Mood disorder	6A60-6E23	Phase 2	[58]
PIPERINE	DMYEAB1	Vitiligo	ED63.0	Phase 1/2	[59]

Drug(s) Targeting Cytoplasmic thioredoxin reductase (TXNRD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fotemustine	DMV62ED	Solid tumour/cancer	2A00-2F9Z	Approved	[2]
Spermidine	DMVJNFI	Plaque psoriasis	EA90.0	Phase 3	[2]
Golden phosphorous acetyletic compound 2	DMYJ15A	N. A.	N. A.	Patented	[11]
Terpyridineplatinum(II) complexe 3	DM54EFD	N. A.	N. A.	Patented	[11]
Terpyridineplatinum(II) complexe 4	DMOV86T	N. A.	N. A.	Patented	[11]
Golden phosphorous acetyletic compound 1	DMVAKUI	N. A.	N. A.	Patented	[11]
Acyl oxymethyl acrylamide ester derivative 1	DMXTUE1	N. A.	N. A.	Patented	[11]
PMID27977313-Compound-18	DMIA3GH	N. A.	N. A.	Patented	[11]
Triazole gold complexe 1	DMCWES7	N. A.	N. A.	Patented	[11]
4-aryl quinol derivative 2	DM7TW5Z	N. A.	N. A.	Patented	[11]

Drug(s) Targeting Trypanosoma Trypanothione reductase (Trypano TPR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vitamin A	DMJ2AH4	Night blindness	9D45	Approved	[60]
Bivalirudin	DMECRX1	Thrombocytopenia	3B64	Approved	[61]
CONESSINE	DM4VYP0	Discovery agent	N.A.	Investigative	[62]
Maleic Acid	DM4L0R7	Discovery agent	N.A.	Investigative	[7]
1-(2'-chlorophenyl)penta-1,4-dien-3-one	DMKTZSY	Discovery agent	N.A.	Investigative	[12]
CEPHARANTINE	DMCE3NA	Discovery agent	N.A.	Investigative	[62]
Trypanothione	DMDUGQ1	Discovery agent	N.A.	Investigative	[2]
N-(5-chloro-2-(phenylthio)phenyl)butyramide	DMHZ256	Discovery agent	N.A.	Investigative	[63]
N1,N2-bis(dihydrocaffeoyl)spermine	DMSDVGQ	Discovery agent	N.A.	Investigative	[62]

Drug(s) Affected By Riboflavin kinase (RFK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[64]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[65]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[66]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[67]
Demecolcine	DMCZQGK	Solid tumour/cancer	2A00-2F9Z	Approved	[68]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[69]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[70]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[71]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[3]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[3]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Flavohemoglobin (Bact hmp)	TTNAW8S	HMP_ECOLI	Inhibitor	[2]
Bacterial Fumarate reductase flavoprotein (Bact frdA)	TTHDSE2	FRDA_HELPY	Inhibitor	[2]
Bacterial UDP-N-acetylenolpyruvylglucosamine reductase (Bact murB)	TTAEOJ4	MURB_ECOLI	Inhibitor	[2]
Cytoplasmic thioredoxin reductase (TXNRD1)	TTR7UJ3	TRXR1_HUMAN	Inhibitor	[2]
Dihydrothymine dehydrogenase (DPYD)	TTZPS91	DPYD_HUMAN	Inhibitor	[2]
Glutathione reductase (GR)	TTEP6RV	GSHR_HUMAN	Inhibitor	[2]
Monoamine oxidase type A (MAO-A)	TT3WG5C	AOFA_HUMAN	Inhibitor	[2]
Monoamine oxidase type B (MAO-B)	TTGP7BY	AOFB_HUMAN	Inhibitor	[2]
Nitric-oxide synthase brain (NOS1)	TTZUFI5	NOS1_HUMAN	Inhibitor	[2]
Quinone reductase 1 (NQO1)	TT8XK6L	NQO1_HUMAN	Inhibitor	[2]
Quinone reductase 2 (NQO2)	TTJLP0R	NQO2_HUMAN	Inhibitor	[2]
Trypanosoma Dihydrolipoamide dehydrogenase (Trypano LPD)	TTBKQL3	DLDH_TRYCR	Inhibitor	[2]
Trypanosoma Trypanothione reductase (Trypano TPR)	TTRTKPV	TYTR_TRYBB	Inhibitor	[2]
Xanthine dehydrogenase/oxidase (XDH)	TT7RJY8	XDH_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Riboflavin kinase (RFK)	OT77IYIS	RIFK_HUMAN	Regulation of Drug Effects	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5184).
• [2] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [3] Involvement of riboflavin kinase expression in cellular sensitivity against cisplatin. Int J Oncol. 2011 Apr;38(4):893-902. doi: 10.3892/ijo.2011.938. Epub 2011 Feb 9.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT01748877) Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia. U.S. National Institutes of Health.
• [6] Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
• [7] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [8] Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.
• [9] Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11.
• [10] The purification and properties of glutathione reductase from the cestode Moniezia expansa. Int J Biochem Cell Biol. 1995 Apr;27(4):393-401.
• [11] Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556.
• [12] Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate. J Med Chem. 2005 Nov 17;48(23):7400-10.
• [13] In vitro inhibition of human erythrocyte glutathione reductase by some new organic nitrates. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3661-3.
• [14] Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87.
• [15] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [16] Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
• [17] Clinical pipeline report, company report or official report of Takeda (2009).
• [18] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [19] Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
• [20] Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
• [21] Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
• [22] QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
• [23] Clinical pipeline report, company report or official report of Teijin Pharma.
• [24] Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
• [25] An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
• [26] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [27] Therapeutic strategies for Leber's hereditary optic neuropathy: A current update. Intractable Rare Dis Res. 2013 November; 2(4): 130-135.
• [28] In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54.
• [29] In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
• [30] Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56.
• [31] Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6.
• [32] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [33] Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84.
• [34] Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66.
• [35] Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer. 2002 Jun;38(9):1271-7.
• [36] Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul;9(7):1635-49.
• [37] Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. Clin Cancer Res. 2004 Apr 1;10(7):2327-35.
• [38] Effects of FL-386 on faecal lipid excretion in humans. J Int Med Res. 1993 Sep-Oct;21(5):225-33.
• [39] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [40] Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
• [41] Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
• [42] Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
• [43] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
• [44] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [45] Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
• [46] Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
• [47] Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
• [48] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [49] Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
• [50] Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
• [51] Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
• [52] Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
• [53] MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
• [54] Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
• [55] Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
• [56] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [57] Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
• [58] Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
• [59] Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
• [60] Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
• [61] 8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase. Mem Inst Oswaldo Cruz. 2003 Jun;98(4):565-8.
• [62] The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors. Bioorg Med Chem. 2008 Jul 15;16(14):6689-95.
• [63] Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class ... J Med Chem. 2005 Dec 15;48(25):8087-97.
• [64] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [65] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [66] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [67] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [68] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [69] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [70] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [71] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.